The Asia Pacific Enteral Feeding Formulas Market is expected to witness market growth of 9.0% CAGR during the forecast period (2022-2028).
Patients with severe Gastroesophageal reflux disease (GERD) may benefit from jejunostomy tubes. Predigested or elemental formula may be required for jejunostomy feeding. Most people handle standard enteral feeding formulae (complete protein, long-chain fat) well. To supply enough energy, calorie-dense formulations (1.5-2.0 kcal/mL) are typically needed. Infusion during the night is encouraged to support regular eating habits during the day. In the beginning, 30-50% of EER is supplied overnight. With enteral feeding, pancreatic enzymes are administered. Both intermittent and continuous enteral feeding is possible. The type of infusion to be used and the method chosen for enteral feeding administration have an impact on the formulation.
Numerous enteral formulations are based on either freshly prepared food, processed food, or a combination of both. As a result, the elements that make up enteral feeding formulas are typically the same as those found in a typical diet and just are taken orally.
The majority of patients in the Asia Pacific region used nasogastric tube feeding (NGT) among the many HEN delivery techniques. There are few prevalence and incidence data on the use of percutaneous endoscopic gastrostomy (PEG) in long-term care facilities (LTCFs) in the Asia Pacific region. A Taiwanese study found a 2.8% prevalence rate, and a second study by Japan estimated that 89,096 PEG patients were present in 2011.
The China market is leading the Asia Pacific Enteral Feeding Formulas Market by Country in 2021; thereby, achieving a market value of $694.1 million by 2028. The Japan market is expected to exhibit to a CAGR of 8.3% during (2022 - 2028). Additionally, The India market is poised to grow at a CAGR of 9.6% during (2022 - 2028).
Based on End User, the market is segmented into Hospitals, Long Term Care facilities, Nursing Homes, Assisted Living Facilities, and Home Care Agencies & Hospices. Based on Application, the market is segmented into Oncology, Neurological Disorders, Gastrointestinal Diseases, Diabetes, and Others. Based on Stage, the market is segmented into Adults and Pediatric. Based on Product, the market is segmented into Standard Formula, Disease specific, Diabetic Formula, Renal Formula, Hepatic Formula, Pulmonary Formula, Peptide-based Formula, Other Disease Specific Formula, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Danone S.A. (Sofina Group), Nestle S.A., Fresenius SE & Co. KGaA, B. Braun Melsungen AG, Otsuka Pharmaceutical Co., Ltd., Meiji Holdings Co., Ltd., Reckitt Benckiser Group PLC, Hormel Foods Corporation and Medline Industries, Inc.
Patients with severe Gastroesophageal reflux disease (GERD) may benefit from jejunostomy tubes. Predigested or elemental formula may be required for jejunostomy feeding. Most people handle standard enteral feeding formulae (complete protein, long-chain fat) well. To supply enough energy, calorie-dense formulations (1.5-2.0 kcal/mL) are typically needed. Infusion during the night is encouraged to support regular eating habits during the day. In the beginning, 30-50% of EER is supplied overnight. With enteral feeding, pancreatic enzymes are administered. Both intermittent and continuous enteral feeding is possible. The type of infusion to be used and the method chosen for enteral feeding administration have an impact on the formulation.
Numerous enteral formulations are based on either freshly prepared food, processed food, or a combination of both. As a result, the elements that make up enteral feeding formulas are typically the same as those found in a typical diet and just are taken orally.
The majority of patients in the Asia Pacific region used nasogastric tube feeding (NGT) among the many HEN delivery techniques. There are few prevalence and incidence data on the use of percutaneous endoscopic gastrostomy (PEG) in long-term care facilities (LTCFs) in the Asia Pacific region. A Taiwanese study found a 2.8% prevalence rate, and a second study by Japan estimated that 89,096 PEG patients were present in 2011.
The China market is leading the Asia Pacific Enteral Feeding Formulas Market by Country in 2021; thereby, achieving a market value of $694.1 million by 2028. The Japan market is expected to exhibit to a CAGR of 8.3% during (2022 - 2028). Additionally, The India market is poised to grow at a CAGR of 9.6% during (2022 - 2028).
Based on End User, the market is segmented into Hospitals, Long Term Care facilities, Nursing Homes, Assisted Living Facilities, and Home Care Agencies & Hospices. Based on Application, the market is segmented into Oncology, Neurological Disorders, Gastrointestinal Diseases, Diabetes, and Others. Based on Stage, the market is segmented into Adults and Pediatric. Based on Product, the market is segmented into Standard Formula, Disease specific, Diabetic Formula, Renal Formula, Hepatic Formula, Pulmonary Formula, Peptide-based Formula, Other Disease Specific Formula, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Danone S.A. (Sofina Group), Nestle S.A., Fresenius SE & Co. KGaA, B. Braun Melsungen AG, Otsuka Pharmaceutical Co., Ltd., Meiji Holdings Co., Ltd., Reckitt Benckiser Group PLC, Hormel Foods Corporation and Medline Industries, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User- Hospitals
- Long Term Care facilities
- Nursing Homes
- Assisted Living Facilities
- Home Care Agencies & Hospices
- Oncology
- Neurological Disorders
- Gastrointestinal Diseases
- Diabetes
- Others
- Adults
- Pediatric
- Standard Formula
- Disease specific
- Diabetic Formula
- Renal Formula
- Hepatic Formula
- Pulmonary Formula
- Peptide-based Formula
- Other Disease Specific Formula
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Danone S.A. (Sofina Group)
- Nestle S.A.
- Fresenius SE & Co. KGaA
- B. Braun Melsungen AG
- Otsuka Pharmaceutical Co., Ltd.
- Meiji Holdings Co., Ltd.
- Reckitt Benckiser Group PLC
- Hormel Foods Corporation
- Medline Industries, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Enteral Feeding Formulas Market by End User
Chapter 5. Asia Pacific Enteral Feeding Formulas Market by Application
Chapter 6. Asia Pacific Enteral Feeding Formulas Market by Stage
Chapter 7. Asia Pacific Enteral Feeding Formulas Market by Product
Chapter 8. Asia Pacific Enteral Feeding Formulas Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Danone S.A. (Sofina Group)
- Nestle S.A.
- Fresenius SE & Co. KGaA
- B. Braun Melsungen AG
- Otsuka Pharmaceutical Co., Ltd.
- Meiji Holdings Co., Ltd.
- Reckitt Benckiser Group PLC
- Hormel Foods Corporation
- Medline Industries, Inc.
Methodology
LOADING...